Makiko Nakamura
Overview
Explore the profile of Makiko Nakamura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
111
Citations
808
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nakamura M, Imamura T, Hida Y, Izumida T, Nakagaito M, Nagura S, et al.
Medicina (Kaunas)
. 2025 Feb;
61(2).
PMID: 40005426
Achieving an optimal balance between thrombosis prevention and bleeding risk during temporary mechanical circulatory support remains a significant clinical challenge. Effective anticoagulation management that ensures device functionality while minimizing major...
2.
Nakamura M, Imamura T, Nakagaito M, Ueno H, Kinugawa K
Int Heart J
. 2024 Dec;
65(6):1049-1057.
PMID: 39617497
The prognosis in patients with acute myocardial infarction-related cardiogenic shock (AMI-CS) remains unsatisfactory even in the era of Impella, especially among the patients who receive concomitant veno-arterial extracorporeal membrane oxygenation...
3.
Nakamura M, Imamura T, Fujioka H, Nakagaito M, Ueno H, Kinugawa K
J Artif Organs
. 2024 Sep;
PMID: 39277833
The spleen size may be associated with mortality and morbidity in patients with heart failure, whereas its clinical implication in patients with cardiogenic shock receiving Impella-incorporated temporary mechanical circulatory support...
4.
Nakamura M, Imamura T, Koichiro K
J Artif Organs
. 2024 Sep;
PMID: 39244693
The utilization of temporary mechanical circulatory support (MCS) in the management of cardiogenic shock is experiencing a notable surge. Acute myocardial infarction remains the predominant etiology of cardiogenic shock, followed...
5.
Nishimura T, Hirata Y, Ise T, Iwano H, Izutani H, Kinugawa K, et al.
J Cardiol
. 2024 Aug;
84(3):208-238.
PMID: 39098794
No abstract available.
6.
Nishimura T, Hirata Y, Ise T, Iwano H, Izutani H, Kinugawa K, et al.
Circ J
. 2024 Jul;
88(8):1347.
PMID: 39048385
No abstract available.
7.
The Impact of the Withdrawal of SGLT2 Inhibitors on Clinical Outcomes in Patients with Heart Failure
Nakagaito M, Imamura T, Ushijima R, Nakamura M, Kinugawa K
J Clin Med
. 2024 Jun;
13(11).
PMID: 38892907
: The clinical impact of the withdrawal of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on all-cause readmission in patients with heart failure remains unknown. : We enrolled a total of 212...
8.
Nakamura M, Imamura T, Hida Y, Izumida T, Nakagaito M, Nagura S, et al.
J Artif Organs
. 2024 Jun;
28(1):30-35.
PMID: 38862744
We encountered a 64-year-old woman who experienced fulminant myocarditis and underwent treatment with veno-arterial extracorporeal membrane oxygenation and Impella CP support. Subsequently, she underwent a device upgrade to Impella 5.5...
9.
Impella support for refractory cardiogenic shock accompanied by diabetic ketoacidosis: a case report
Nakagaito M, Nakamura M, Imamura T, Ueno H, Kinugawa K
J Artif Organs
. 2024 May;
28(1):78-82.
PMID: 38797808
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are strongly recommended in patients with heart failure, regardless of the presence of diabetes mellitus. A 74 year-old woman with a reduced left ventricular ejection...
10.
Nishimura T, Hirata Y, Ise T, Iwano H, Izutani H, Kinugawa K, et al.
Circ J
. 2024 Apr;
88(6):1010-1046.
PMID: 38583962
No abstract available.